Parker Charles Nolan 4

What Happened Parker Charles Nolan, Chief Financial Officer of Traws Pharma, received a series of equity awards totaling 213,914 units across four grants. The awards (reported as acquisitions at $0.00) consist of 15,393 restricted stock units (RSUs) and three stock-option grants totaling 198,521 option units (32,406; 61,571; 104,544). These were grants/awards (non-cash compensation), not open-market purchases or sales.

Key Details

• Transaction dates and amounts:
  • 2025-12-12: 15,393 RSUs granted at $0.00 (F1).
  • 2025-10-12: 32,406 stock options granted at $0.00 (F2).
  • 2025-12-12: 61,571 stock options granted at $0.00 (F3).
  • 2026-03-08: 104,544 stock options granted at $0.00 (F4).
• Total awards reported: 213,914 units.
• Vesting/terms: RSUs convert one-for-one into common shares and, per footnotes, each stock-option award vests 100% on the first anniversary of its grant date. Awards were approved by the issuer’s compensation committee (independent directors).
• Shares owned after transaction: not disclosed in the filing.
• Filing timeliness: Form filed 2026-04-08; the earliest reported grant was 2025-10-12 — the filing appears late relative to the transaction dates.

Context

• RSUs and stock options are compensation vehicles: RSUs convert to shares on vesting; options give the right to buy shares subject to exercise and any applicable strike price. These awards are not immediate market purchases or sales and will only affect outstanding common stock if/when RSUs vest or options are exercised.
• Because the filing is a grants/awards report rather than a purchase, it signals compensation activity rather than a direct insider buy or sell of shares.